Aelis Farma

AELIS

FR0014007ZB4

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 05:57:32 31/05/2024 pm IST			5-day change	1st Jan Change
13.2 ^EUR	+0.76%		+0.76%	+0.76%

18/04	Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder	CI
02/04	Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aelis Farma S.A. has completed an IPO in the amount of €25.000001 million.

February 15, 2022 at 10:30 am IST

Aelis Farma S.A. has completed an IPO in the amount of €25.000001 million.

Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,646,952
PriceRange: €14.02

Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 136,215
PriceRange: €14.02

Transaction Features: Sponsor Backed Offering

Latest news about Aelis Farma

Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder	18/04	CI
Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Aelis Farma Appoints Chief Corporate Development Officer	18/01	MT
Aelis Farma Announces the Appointment of Arsène Guekam as Chief Corporate Development Officer	17/01	CI
Aelis Farma Announces Completion of Patient Randomization for Phase 2B Study with Aef0117 for the Treatment of Cannabis Addiction	09/01	CI
Aelis Farma Announces Positive Results of Non-Clinical Studies Required by Regulatory Agencies to Enter Its First Cb1-SSI, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder	07/11	CI
Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Aelis Farma: CEO and co-founder recognized by his peers	29/23/29	CF
Data Safety Monitoring Board OKs Aelis Farma's Mid-stage Trial of Cannabis Addiction Drug	05/23/05	MT
Aelis Farma: received a positive opinion from the DSMB	05/23/05	CF
Aelis Farma Receives a Positive Recommendation From the DSMB to Continue, With No Modification to the Protocol, the Phase 2b Clinical Study With AEF0117 in Cannabis Addiction	05/23/05	CI
Aelis Farma: favorable preclinical data in autism	12/23/12	CF
Aelis Farma Announces the Presentation of New Preclinical Data on its Drug Candidate AEF0217 at the 2nd European Conference on Phelan-McDermid Syndrome	12/23/12	CI
CAC40: ends in green, ignores eurozone recession	08/23/08	CF
Aelis Farma: promising results for AEF0117	08/23/08	CF
Aelis Farma SA Approves Transfer of Registered Office	25/23/25	CI
AELIS FARMA : Degroof Petercam initiates buy coverage	24/23/24	CF
Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2022	03/23/03	CI
Aelis Farma Begins Patient Recruitment for Trial of Cognitive Disorder Treatment	16/22/16	MT
Aelis Farma S.A Announces the Recruitment of the First Patient for the Phase 1/2 Clinical Trial of Its Drug Candidate AEF0217 for the Treatment of Cognitive Disorders in Down Syndrome	16/22/16	CI
Aelis Farma Announces Positive Results from Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217	15/22/15	CI
Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2022	26/22/26	CI
Indivior's Cannabis Use Disorder Treatment Enrolls First Patient For Phase 2b Trial	01/22/01	MT
Aelis Farma S.A. Announces the Inclusion of the 1st Patient in A Phase 2B Study of AEF0117 for the Treatment of Cannabis Use Disorder	01/22/01	CI
Biopharmaceutical Company Aelis Farma Secures $28 Million in Paris IPO	16/22/16	MT

Chart Aelis Farma

Duration

Period

More charts

Company Profile

Aelis Farma is specialized in the research and development of drugs for the treatment of major disorders of the Central Nervous System (CNS). The company has 2 products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome, Fragile X syndrome, Subjective Memory Impairment (SMI) and Alzheimer's disease).

Sector

Pharmaceuticals

Calendar

03/06/2024 - BIO International Convention

More about the company

Income Statement Evolution

More financial data

Ratings for Aelis Farma

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.2 EUR

Average target price

20.67 EUR

Spread / Average Target

+56.57%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AELIS FARMA	+0.76%	19Cr
ELI LILLY AND COMPANY	+40.73%	73TCr
NOVO NORDISK A/S	+32.83%	59TCr
JOHNSON & JOHNSON	-6.30%	35TCr
MERCK & CO., INC.	+15.15%	32TCr
ABBVIE INC.	+4.05%	28TCr
ASTRAZENECA PLC	+15.00%	24TCr
NOVARTIS AG	+9.78%	21TCr
ROCHE HOLDING AG	-5.52%	20TCr
AMGEN INC.	+6.17%	16TCr

Other Pharmaceuticals

Aelis Farma

Equities

AELIS

FR0014007ZB4

Pharmaceuticals

Aelis Farma S.A. has completed an IPO in the amount of €25.000001 million.

Latest news about Aelis Farma

Chart Aelis Farma

Company Profile

Income Statement Evolution

Ratings for Aelis Farma

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals